122 related articles for article (PubMed ID: 15131522)
1. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update.
DeVane CL; Mintzer J
Psychopharmacol Bull; 2003; 37(4):116-32. PubMed ID: 15131522
[TBL] [Abstract][Full Text] [Related]
2. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
3. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
4. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
6. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
7. Advances in pharmacotherapy of psychotic disorders in the elderly.
Kirkwood CK; Givone DM
Consult Pharm; 2003 Jun; 18(6):539-50. PubMed ID: 16563063
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience and management considerations with long-acting risperidone.
Parellada E
Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
[TBL] [Abstract][Full Text] [Related]
9. Long-acting risperidone: focus on safety.
Möller HJ
Clin Ther; 2006 May; 28(5):633-51. PubMed ID: 16861087
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
11. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Aman MG; Gharabawi GM;
J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Kissling W; Glue P; Medori R; Simpson S
Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
[TBL] [Abstract][Full Text] [Related]
13. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
[TBL] [Abstract][Full Text] [Related]
16. Risperidone: review of its therapeutic utility in depression.
Myers JE; Thase ME
Psychopharmacol Bull; 2001; 35(4):109-29. PubMed ID: 12397861
[TBL] [Abstract][Full Text] [Related]
17. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
Curran S; Turner D; Musa S; Wattis J
Int J Geriatr Psychiatry; 2005 Sep; 20(9):842-7. PubMed ID: 16116576
[TBL] [Abstract][Full Text] [Related]
20. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
Chengappa KN; Sheth S; Brar JS; Parepally H; Marcus S; Gopalani A; Palmer A; Baker RW; Schooler NR
J Clin Psychiatry; 1999 Jun; 60(6):373-8. PubMed ID: 10401915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
